Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmpeak Energy Regulatory News (AMP)

Share Price Information for Ampeak Energy (AMP)

Share Price is delayed by 15 minutes
Get Live Data
3.00    0.00 (0.00%)
Bid:
2.80
Ask:
3.20
Spread: 0.40 (14.286%)
Market Cap: £21.68m
AMP Live PriceLast checked at - London Stock Exchange

Intraday Ampeak Energy Share Chart

AGM Statement

8 Jun 2006 07:03

Amphion Innovations PLC08 June 2006 Amphion Innovations plc Annual General Meeting Trading Update London, UK, 8 June 2006 - The Annual General Meeting of Amphion Innovations plc(LSE: AMP), the developer of companies in the life sciences and medicaltechnology sectors, will be held in London today. We are providing thefollowing trading update summarising promising progress made regarding some ofour Partner Companies following on from the preliminary results announcement of8 March 2006: Durham Scientific Crystals, Ltd. We are delighted to announce that Durham Scientific Crystals (DSC) this pastmonth won the prestigious North East Business Association's Regional InnovationCompany of the Year Award for 2006, sponsored by Barclay's Bank. DSC hadpreviously won the North East Business Association's regional "TechnologyCompany of the Year" award in 2005, sponsored by O2. Based in England's NorthEast region, DSC is advancing world-leading technology developed at DurhamUniversity, dedicated to the field of medical imaging. DSC also recently won a development contract worth £680,000 (approximately US$1.3 million) from Cenamps (the Centre of Excellence for Nano, Micro andPhotonics Systems) to create a new product. DSC will retain rights to both theproduct and the IP resulting from its creation. Says Mike Pitkethly, CEO of Cenamps, "Durham Scientific Crystals hasdemonstrated a continued ability to innovate boldly and with great success.Cenamps is delighted to support the continued development of a regional companythat has world-wide potential." Motif BioSciences, Inc. Motif recently announced a relationship with the Shafallah Centre for Childrenwith Special Needs, which opened last month in Doha, Qatar. Motif BioSciences,Inc., played an instrumental role in the design and development of the ShafallahCentre's Genetics Medical Centre, assisting in the procurement, identifyingleading instrument vendors, and assisting in the installation of afirst-of-its-kind genetics laboratory dedicated to conducting research ondisorders that afflict the children of Qatar. Motif is delighted to today announce the hire of Zaki Hosny as deputy chairmanand chief executive officer. Mr. Hosny comes to Motif from Merck and Company,Inc., where he most recently held the position of vice president of marketingand operations for Europe, the Middle East and Africa. In that role, he wasresponsible for the development of marketing strategies for the entire productportfolio of the region. Prior to that he was the vice president and regionaldirector for Merck's mid-European region, and during that time he successfullysupervised business units with sales of over $1 billion. Axcess International Inc. AXCESS International, Inc., a leading provider of Radio Frequency Identification(RFID) systems, last week completed an additional capital raise of $1.2 million,bringing the total raised in the recent campaign to $3.5 million. The funds areto be used in part to complete the development of a new RFID product designed tofurther exploit AXCESS' existing markets utilising asset, personnel, and vehicletagging. AXCESS booked record RFID revenue of $453,563 for the first quarter of 2006, anincrease of 88% from the same quarter in 2005 and 9% from the fourth quarter of2005. On 6 June 2006, AXCESS announced a solution for managing and securing criticalcomputer assets which hold privacy data. The ActiveTagTM RFID solution isapplicable to data centres, record departments and enterprise operations wherecomputer assets must be accounted for and protected to be in compliance withFederal and State Laws. Supertron, Inc. Supertron presented at the May 2006 show of the International Society forMagnetic Resonance in Medicine (ISMRM), where they displayed the first-evercommercially available superconducting coils for magnetic resonance imaging(MRI) machines. The products had an outstanding reception and Supertron expectsthem to ship later in 2006. WellGen, Inc. Amphion mourns with great sorrow the sudden and unexpected passing last week ofDr. David Evans, CEO of WellGen. Our thoughts remain with his co-workers andhis family. WellGen today announces the addition to its management team of Steve Sisk asdirector of clinical operations. Steve Sisk has a background including morethan 10 years of pharmaceutical and biotech industry experience (including NovoNordisk, Nektar Therapeutics and Applied Biosystems) involving CRO managementand negotiations, clinical study planning and the execution and direction oflarge cross-functional development teams. Steve received his BS in plantgenetics from Cornell University and his MS from the University of Wisconsin,where he specialised in plant biochemistry and natural products drugs. Richard Mansell-Jones, Chairman of Amphion, said: "We are delighted with the strong progress made by our Partner Companies sincethe March release of our preliminaries. "We look towards the remainder of 2006 with great confidence." Enquiries: Amphion Innovations plcRichard Morgan, Chief Executive +1 (212) 210-6224Aaron Kwittken, Media Relations +1 (646) 747-7144 Financial Dynamics +44 207 269 7169Ben AtwellJohn Gilbert Notes to editors: About Amphion Innovations plc Amphion Innovations plc is quoted on AIM market of the London Stock Exchangeunder the symbol AMP. Amphion's business is the formation, financing,management and development of life sciences and technology companies, working inpartnership with corporations, governments, universities and entrepreneursseeking to commercialise their intellectual property. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Jan 20167:00 amRNSConvertible Promissory Note Terms Extended
26th Nov 20157:00 amRNSAdditional Draw on Loan Facility
5th Nov 20157:00 amRNSPartner Company m2m Imaging Corp. to merge
30th Oct 20154:20 pmRNSDeath of a Director - Replacement
30th Oct 20153:50 pmRNSDeath of a Director
17th Sep 20157:00 amRNSAmphion to present in London
16th Sep 20157:00 amRNSDirectors' Dealings
10th Sep 20157:00 amRNSDataTern Receives Favourable Ruling
3rd Sep 20157:00 amRNSInterim Results
28th Aug 20159:08 amRNSHolding(s) in Company
7th Aug 20155:15 pmRNSResult of AGM
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied
1st Jul 20155:07 pmRNSHolding(s) in Company
23rd Jun 20158:47 amRNSPartner Company raises £22 million
23rd Jun 20157:00 amRNSPreliminary Results
5th Jun 20157:00 amRNSPlacing to raise £1.54 million
19th May 20152:35 pmRNSAppointment of broker
15th Apr 20157:01 amRNSFDA Results
7th Apr 20157:00 amRNSShares Issued for Exercised Warrants
2nd Apr 20157:01 amRNSFirst Day of Dealings of Amphion Partner Company
24th Mar 20153:28 pmRNSIssue of Shares
20th Mar 20157:01 amRNSMotif Bio Ltd Update Re Intention to Float
26th Feb 20157:00 amRNSIssue of Equity
9th Feb 20157:00 amRNSDirector/PDMR Shareholding
2nd Feb 20154:18 pmRNSReissue: Partner Company's Intention to Float
2nd Feb 20158:00 amRNSPartner Company's Intention to Float on AIM
22nd Jan 20151:15 pmRNSDirector/PDMR Shareholding
19th Jan 20157:00 amRNSLandmark Acquisition & Update by Partner Company
6th Jan 20157:00 amRNSDataTern Receives Favourable Appeal Ruling
24th Sep 20147:00 amRNSDirectors' Dealings
19th Sep 20147:00 amRNSHalf Yearly Report
9th Sep 20147:00 amRNSAdditional Draws on Loan Facility
28th Aug 20147:00 amRNSDirectorate Change
7th Aug 20144:51 pmRNSResult of AGM and EGM
10th Jul 20149:10 amRNSDirectors' Dealings
8th Jul 20147:00 amRNSAmphion Partner Motif Can Help Solve Health Crisis
20th Jun 20147:00 amRNSNotice of EGM
18th Jun 20147:00 amRNSFinal Results
5th Jun 20147:00 amRNSNew Loan Facility
14th Apr 20147:00 amRNSAppeal Ruling
7th Apr 20145:03 pmRNSDirector/PDMR Shareholding
28th Jan 20147:00 amRNSConvertible Promissory Note Extension
12th Dec 20137:00 amRNSUpdate on Covertible Promissory Note
13th Nov 20134:33 pmRNSDirector/PDMR Shareholding
13th Nov 20137:00 amRNSPartner Company Update
16th Oct 20137:02 amRNSPartner Company IPO
24th Sep 20137:00 amRNSHalf Yearly Report
12th Sep 20137:02 amRNSPartner company Kromek seeks IPO on AIM
13th Aug 20135:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.